ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

acalabrutinib

Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.

Drug pageAcalabrutinib: every studyAll 123 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 11, 202155 company-led studies, 22 open or runningNext primary completion: Feb 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca5220 open or runningphase 4since Jun 11, 2021Jan 6, 2014Feb 15, 2027phase 3 · NCT02972840
AbbVieits history only11 open or runningphase 3since May 20, 2024May 20, 2024Mar 2028phase 3 · NCT06428019
Ascentage Pharma Group Internationalits history only11 open or runningphase 3since Mar 13, 2024Mar 13, 2024Aug 2027phase 3 · NCT06319456
Ipsenits history only10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 34 earlier studies, Jan 6, 2014 to Jul 27, 2020.

  1. Jun 9, 2015Named acalabrutinibINNProposed as its International Nonproprietary Name in WHO's List 113 · before, ACP-196
  2. Aug 25, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04529772 · 611 enrolled · United States, Australia, Austria and more
  3. Aug 27, 2020Phase 1 study in Lymphoma, Mantle-CellNCT04564040 · 20 enrolled · Germany
  4. Feb 22, 2021Phase 1 study in BioequivalenceNCT04768985 · 66 enrolled · United States
  5. Apr 28, 20212 phase 1 studiesNCT04867980, NCT04867941
  6. May 5, 20215 phase 1 studiesNCT04876807, NCT04901923, NCT04914936 and 2 more
  7. Jun 11, 2021Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04930536 · 103 enrolled · India
  8. Sep 16, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05057494 · 607 enrolled · United States, Australia, Czechia and more
  9. Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellNCT05951959 · 108 enrolled · United States, Australia, Brazil and more
  10. Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
  11. Aug 20, 2024Phase 4 study in Leukemia, B-CellNCT06651970 · 60 planned · United States, Czechia, Italy and more
  12. Jan 21, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06839872
  13. May 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07024706 · 80 planned · United States, Austria, Brazil and more
  14. Jun 12, 2025Phase 2 study in Lymphoma, Mantle-CellNCT07029737 · 55 planned · Spain
  15. Oct 5, 2026Primary completion moved from 2027-01-31 to 2027-04-30Date moved laterphase 3 · +3 months · NCT03836261

Ahead

  1. Feb 15, 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellNCT02972840
  2. Feb 22, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04529772
  3. Apr 30, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03836261
  4. Jul 15, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05057494

TargetBeta

BTK →read by rule
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 52 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07029737Lymphoma, Mantle-Cell · Spain2RecruitingDec 31, 202755
NCT07024706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Brazil and more2RecruitingMay 1, 202980
NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnJul 28, 20280
NCT06651970Leukemia, B-Cell · United States, Czechia, Italy and more4RecruitingSep 30, 203260
NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more2RecruitingApr 22, 202980
NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more2Active, not recruitingOct 31, 2028108
NCT05057494Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Czechia and more3Active, not recruitingJul 15, 2027607
NCT04930536Leukemia, Lymphocytic, Chronic, B-Cell · India4CompletedMay 2, 2023103
NCT04905043Healthy Volunteers · United States1CompletedJul 11, 201612
NCT04914936Healthy Participants · United States1CompletedOct 16, 201472
NCT04898101Healthy Volunteers · United States1CompletedApr 13, 201614
NCT04901923Healthy Participants · United States1CompletedMay 22, 201459
NCT04876807Healthy Volunteers · United States1CompletedMar 15, 201636
NCT04867980Healthy Volunteers · United States1CompletedMay 9, 201648
NCT04867941Hepatic Insufficiency · United States1CompletedFeb 2, 201518
NCT04768985Bioequivalence · United States1CompletedMay 10, 202166
NCT04564040Lymphoma, Mantle-Cell · Germany1CompletedDec 11, 202020
NCT04529772Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3Active, not recruitingFeb 22, 2027611
NCT04489797Communicable Diseases · United States1CompletedAug 28, 202035
NCT04497948COVID-19 · Brazil1TerminatedNov 18, 20209
NCT04435483Pharmacokinetics · United States1CompletedJun 26, 202039
NCT04380688COVID-19 · United States2CompletedNov 16, 202062
NCT04346199COVID-19 · Argentina, Brazil, Chile and more2CompletedNov 17, 2020177
NCT04075292Leukemia, Lymphocytic, Chronic, B-Cell · China, Philippines, Taiwan and more3Active, not recruitingJan 3, 2024155
NCT04008706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more3CompletedNov 4, 2025552
NCT03968848Hepatic Insufficiency · United States1CompletedMar 13, 201916
NCT03932331Lymphoma, Mantle-Cell · China2Active, not recruitingDec 22, 2022105
NCT03836261Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3Active, not recruitingApr 30, 2027984
NCT03205046DLBCL · United States, United Kingdom2TerminatedNov 20, 201925
NCT03198650Part1: Advanced B-cell Malignancies · Japan1CompletedOct 27, 202235
NCT02972840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more3Active, not recruitingFeb 15, 2027635
NCT02970318Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingSep 3, 2021310
NCT02735876Lymphoma, Mantle-Cell3WithdrawnJun 20200
NCT02717611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, France and more2Active, not recruitingOct 16, 202060
NCT02717624Lymphoma, Mantle-Cell · United States, Italy, Poland1Active, not recruitingJun 15, 202272
NCT02586857Glioblastoma · United States2Active, not recruitingJun 26, 202024
NCT02537444Ovarian Neoplasms · United States2CompletedJul 201878
NCT02477696Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3Active, not recruitingSep 15, 2020533
NCT02475681Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedFeb 8, 2019535
NCT02454179Squamous Cell Carcinoma of Head and Neck · United States2CompletedMay 201878
NCT02448303Carcinoma, Non-Small-Cell Lung · United States2CompletedMar 201874
NCT02387762Arthritis, Rheumatoid · United States2CompletedMay 201631
NCT02362035Lymphoma, Follicular · United States2CompletedJul 14, 2020161
NCT02362048Pancreatic Neoplasms · United States2CompletedMar 201777
NCT02351739Carcinoma, Transitional Cell · United States2CompletedFeb 201878
NCT02337829Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedJun 26, 202048
NCT02213926Lymphoma, Mantle-Cell · United States, Australia, Belgium and more2Active, not recruitingDec 4, 2020124
NCT02211014Multiple Myeloma · United States, United Kingdom1CompletedApr 26, 201927
NCT02180724Waldenstrom Macroglobulinemia · United States, France, Greece and more2Active, not recruitingOct 1, 2019107
NCT02180711Lymphoma, Non-Hodgkin · United States, Canada, Italy2Active, not recruitingAug 25, 2023113
NCT02112526Lymphoma, Large B-Cell, Diffuse · United States, United Kingdom1CompletedJun 30, 202021
NCT02029443Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, United Kingdom2Active, not recruitingJul 15, 2021306

How it is read

Names in the registry

  • “Acalabrutinib”, 28 entries
  • “acalabrutinib”, 7 entries
  • “ACP-196”, 7 entries
  • “Acalabrutinib (ACP-196)”, 3 entries
  • “ACP-196 (acalabrutinib)”, 2 entries

Codes read as this program: ACP196.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.